Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

1. Patients, men and women =/> 55 years of age.

2. Inpatient / Outpatients with diagnosis of Moderate to Severe probable Alzheimer's dementia as determined by the Structured Clinical Interview for DSM-IV.

3. Patients with a Mini Mental Status Examination scores between 3-15 at screening.

4. Patients and Care Giver/ Legal representative or Guardian who are able to comprehend and satisfactorily comply with protocol requirements.

5. Patient, Care Giver/ Legal representative or Guardian who signed the written informed consent given prior to entering any study procedure.

6. Patients who have been at least three month ongoing stable dose of cholinesterase enzyme inhibitors or memantine

1. Patients with a concurrent DSM-IV Axis I diagnosis in any of the following categories:

1.1. Delirium, Amnestic and other Cognitive disorders 1.2. Lifetime Schizophrenia and other Psychotic Disorders 1.3. Lifetime Bipolar I Disorder 1.4. Bipolar 11 Disorder with an episode of hypomania within the last year 1.5. Alcohol or Substance Dependence or Abuse (excluding nicotine) in one month prior to the Screening Visit

2. Patients with a history of intolerance or hypersensitivity to Divalproex ER \& Quetiapine.

3. Patients who have a history of seizures.

4. Patients who based on history or mental status examination have a significant risk of committing suicide.

5. Patients who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.

6. Patients who have been treated with depot-neuroleptic within 3 months prior to the Baseline Visit.

7. Patients with a positive urine drug screen, unless proven to be prescribed for a short-term course of treatment. In these situations a urine drug screen must be repeated at least 7 days after the last dose of the prescription medication containing narcotics.

8. Patients who have participated in any clinical trial within one month prior to the Screening Visit, or in a clinical trial involving a psychotropic medication within the 3 months prior to the Screening Visit.

9. Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.

10. Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.

11. Patients with systolic blood pressure greater than 180 mm Hg or less than 90 mm Hg or diastolic blood pressure greater than 105 mm Hg or less than 50 mm Hg at the Screening visit.

12. Patients who test positive for Hepatitis B surface antigen or Hepatitis C antibody.

13. Patients whose laboratory values at the Screening visit will be 1.5 times greater than ULN.

14. Patients requiring concomitant treatment with any psychotropic drug (except zolpidem for sleep no more than 3x/week prn).

15. Patients who require concomitant therapy with any prohibited prescription.

16. Patients who are unable to speak, read, and understand English or are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.